blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3266466

EP3266466 - LIQUID ANTIBODY FORMULATION WITH IMPROVED AGGREGATION PROPERTIES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.10.2020
Database last updated on 08.10.2024
FormerRequest for examination was made
Status updated on  08.12.2017
Most recent event   Tooltip30.10.2020Application deemed to be withdrawnpublished on 02.12.2020  [2020/49]
Applicant(s)For all designated states
Medimmune, LLC
One Medimmune Way
Gaithersburg, Maryland 20878 / US
[2018/02]
Inventor(s)01 / MALIK, Priyanka
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
02 / SHAH, Ambarish
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
03 / TUESCA, Anthony
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
 [2018/02]
Representative(s)AstraZeneca Intellectual Property
Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF / GB
[N/P]
Former [2018/02]AstraZeneca
Milstein Building
Granta Park
Cambridge CB21 6GH / GB
Application number, filing date17163164.118.12.2013
[2018/02]
Priority number, dateUS201261740193P20.12.2012         Original published format: US 201261740193 P
[2018/02]
Previously filed application, dateWO2013US7606218.12.2013
[2018/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3266466
Date:10.01.2018
Language:EN
[2018/02]
Search report(s)(Supplementary) European search report - dispatched on:EP09.10.2017
ClassificationIPC:A61K39/395, A61P35/00, C07K16/22
[2018/02]
CPC:
A61K39/39591 (EP,US); A61P35/00 (EP); C07K16/22 (EP,US);
C07K2317/51 (US); C07K2317/515 (US); C07K2317/565 (US);
C07K2317/90 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/02]
TitleGerman:FLÜSSIGE ANTIKÖRPERFORMULIERUNG MIT VERBESSERTEN AGGREGIERUNGSEIGENSCHAFTEN[2018/02]
English:LIQUID ANTIBODY FORMULATION WITH IMPROVED AGGREGATION PROPERTIES[2018/02]
French:FORMULATION D'ANTICORPS LIQUIDE AYANT DES PROPRIÉTÉS D'AGRÉGATION AMÉLIORÉES[2018/02]
Examination procedure27.03.2017Date on which the examining division has become responsible
27.04.2017Examination requested  [2018/02]
10.07.2018Amendment by applicant (claims and/or description)
01.07.2020Application deemed to be withdrawn, date of legal effect  [2020/49]
28.07.2020Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2020/49]
Parent application(s)   TooltipEP13866178.0  / EP2934588
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
25.04.2017Renewal fee patent year 04
12.12.2017Renewal fee patent year 05
02.01.2019Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.12.201907   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]US2011044998  (BEDIAN VAHE [US], et al) [I] 1-16 * abstract,paragraphs [0015]-[0040], [0073]-[0081], [0132]-[0136], [0291]-[0304], Example 3 and Table 3 *;
 [A]WO2006068953  (ABGENIX INC [US], et al) [A] 1-16 * the whole document *;
 [A]  - María Vázquez-Rey, "Aggregates in Monoclonal Antibody Manufacturing Processes", vol. 108, no. 7, (20110407), URL: http://onlinelibrary.wiley.com/doi/10.1002/bit.23155/pdf, (20130513), XP055062628 [A] 1-16 * abstract, p. 1501 left-hand column second full paragraph - p. 1502 left-hand column first full paragraph, p. 1503 right-hand column first full paragraph - p. 1504 right-hand column second full paragraph, Tables I and II *
 [A]  - XIAOLING WANG ET AL, "Potential aggregation prone regions in biotherapeutics : A survey of commercial monoclonal antibodies", MABS, US, (20090501), vol. 1, no. 3, doi:10.4161/mabs.1.3.8035, ISSN 1942-0862, pages 254 - 267, XP055410727 [A] 1-16 * abstract, p. 260 left-hand column first-paragraph - p. 264 left-hand column last full paragraph, p. 265 left-hand column last full paragraph - right-hand column line 12, Fig. 1-5 and Tables 2 and 3 *

DOI:   http://dx.doi.org/10.4161/mabs.1.3.8035
 [A]  - LISA A. KUELTZO ET AL, "Effects of Solution Conditions, Processing Parameters, and Container Materials on Aggregation of a Monoclonal Antibody during Freeze-Thawing", JOURNAL OF PHARMACEUTICAL SCIENCES, (20080501), vol. 97, no. 5, doi:10.1002/jps.21110, ISSN 0022-3549, pages 1801 - 1812, XP055410670 [A] 1-16 * abstract, p. 1808 right-hand column last 3 lines - p. 1811 right-hand column line 27 *

DOI:   http://dx.doi.org/10.1002/jps.21110
 [A]  - JARED S. BEE ET AL, "Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies", JOURNAL OF PHARMACEUTICAL SCIENCES, (20090901), vol. 98, no. 9, doi:10.1002/jps.21768, ISSN 0022-3549, pages 3218 - 3238, XP055410673 [A] 1-16 * abstract, p. 13 first paragraph - p. 17 line 22 *

DOI:   http://dx.doi.org/10.1002/jps.21768
 [A]  - MATTHEW HOEHNE ET AL, "Adsorption of Monoclonal Antibodies to Glass Microparticles", JOURNAL OF PHARMACEUTICAL SCIENCES, (20110101), vol. 100, no. 1, doi:10.1002/jps.22275, ISSN 0022-3549, pages 123 - 132, XP055410696 [A] 1-16 * abstract, p. 129 right-hand column second full paragraph - p. 131 right-hand column second full paragraph *

DOI:   http://dx.doi.org/10.1002/jps.22275
 [A]  - Ruth V Cordoba-Rodriguez, "Aggregates in MAbs and Recombinant Therapeutic Proteins: A Regulatory Perspective", (20081101), URL: http://www.biopharminternational.com/print/234065?page=full, (20170908), XP055405208 [A] 1-16 * the whole document *
by applicantUS3773919
 EP0058481
 US2006246071
    - LANGER et al., J. Biomed Mater. Res., (19810000), vol. 15, pages 167 - 277
    - LANGER, Chem. Tech., (19820000), vol. 12, pages 98 - 105
    - SIDMAN et al., Biopolymers, (19830000), vol. 22, pages 547 - 556
    - KABAT et al., Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication 91-3242, (19910000), vol. 1-3
    - HUSTON, J. S. et al., Proc. Natl. Acad. Sci. U.S.A., (19880000), vol. 85, pages 5879 - 5883
    - CO, M. S. et al., T. Immunol., (19940000), vol. 152, pages 2968 - 2976
    - BETTER, M.; HORWITZ, A. H., Methods Enzymol., (19890000), vol. 178, pages 476 - 496
    - PLUCKTHUN, A.; SKERRA, A., Methods Enzymol., (19890000), vol. 178, pages 497 - 515
    - LAMOYI, E., Methods Enzymol, (19860000), vol. 121, pages 652 - 663
    - ROUSSEAUX, J. et al., Methods Enzymol., (19860000), vol. 121, pages 663 - 669
    - BIRD, R. E.; WALKER, B. W., Trends Biotechnol., (19910000), vol. 9, pages 132 - 137
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.